Antimicrobial activity of enrofloxacin in vitro

Continuouse use of enrofloxacin contributes to emergence of enrofloxacin-resistant microbial resistance, isolated and reported lately. In this study we deal with the spread of resistance of enrofloxacin among pathogenic organisms, infecting animals. The susceptibility to enrofloxacin was studied in standard disc diffusion assay. We studied 437 bacterial isolates in total. Salmonella dublin and Salmonella typhimurium showed the highest susceptibility to enrofloxacin (100%); Salmonella enteritidis and Salmonella choleraesuis proved a bit less susceptibility (95% and 94,7%). 5% of S. enteritidis isolates and 5.3% of S. choleraesuis isolates had intermediate susceptibility. We did not register any resistance of isolates of Salmonella, Pasteurella and Morganella (Pasteurella multocida, Morganella morganii). 83.9% of Escherichiacoli strains proved susceptibility to enrofloxacin, the zone of retardation in 6.4% of the isolates was in correspondence with intermediate susceptibility, 9.7% of the isolates proved to be resistant. 90,9% of Pseudomonas aeruginosa isolates in our study was susceptible to enrofloxacin, 9.1% of them had intermediate susceptibility. The isolates of Streptococcus spp. and Staphylococcus pseudntermedius revealed high susceptibility to enrofloxacin, also as Listeria monocytogenes (causative agent of listeriosis)and Eysipelothrix rhusiopathiae (causative agent of swine erysipelas) 87.5% of the coagulase negative staphylococci proved susceptible to enrofloxacin; 625% of the isolates were resistant or had intermediate susceptibility. The shares of susceptible isolates of Staphylococcus hyicus, Staphylococcus aureus and Streptococcus uberis were respectively 65.1% 75% 75%. The shares of isolates with intermediate susceptibility of the same spp. were respectively 9.3% 15% 25%. The shares of resistant isolates of Staphylococci were respectively 25.6% and 10%. We found no strains of Str. uberis with resistance to enrofloxacin. As for Enterococci, 52.4% of the isolates were enrofloxacin-susceptible, 11,9% and 37,7% of them were respectively enrofloxacin-resistant or had intermediate susceptibility. Presently most Gram-negative pathogenic bacteria have no resistance to enrofloxacin. Notwithstanding that enrofloxacin is significantly less effective against such pathogenic organisms as Staphylococci and Streptococci.

энрофлоксацин, диско-диффузионный метод, резистентность, чувствительность, бактериальные возбудители, enrofloxacin, disco-diffusion method, resistance, sensitivity, pathogens of bacterial infections

1. Лабораторные исследования в ветеринарии: справ. / cocт.: Б.И. Антонов, В.В. Борисова, П.М. Волкова, Л.П. Каменева, Л.В. Кошеленко, Г.А. Михальский, В.В. Поповцев, Л.И. Прянишникова, В.Е. Храпова; под ред. Б.И. Антонова. - Москва: Агропромиздат, 1986. -352 С

2. Лыско, С.Б. Резистентность к энрофлоксацину и возможность ее преодоления / С.Б. Лыско, Л.М. Кашковская, М.И. Сафарова // Птицеводство. - 2016. - № 10. - С. 37-40.

3. Микробиологическая диагностика бактериальных болезней животных: справ. / Д.И Скородумов, В.В. Субботин, М.А Сидоров, Т.С. Костенко. - Москва: Изографъ, 2005. - 656 С.

4. Определение чувствительности микроорганизмов к антибактериальным препаратам: метод, указания МУК 4.2.1890-04 / сост. Н.А. Семина, С.В. Сидоренко, С. П. Резван [и др.]. - Москва, 2004. - 91 c.

5. Чувствительность возбудителей бактериальных болезней животных к офлоксацину / Д.В. Юрин, В.Н. Скворцов, А.А. Балбуцкая, С.С. Белимова, О.А. Манжурина // Актуальные вопросы сельскохозяйственной биологии. - 2019. - № 2 (12). - С. 46-51.

6. Чувствительность возбудителей бактериальных болезней животных к ципрофлоксацину / Д.В. Юрин, В.Н. Скворцов, А.А. Балбуцкая, С.С. Белимова // Международный вестник ветеринарии. - 2019. - № ° 1. - С. 91-95. Чувствительность патогенной микрофлоры к норфлоксацину / Д.В. Юрин, А.А Балбуцкая, В.Н. Скворцов, Белимова С.С. // Международный вестник ветеринарии. - 2019. - № °3. - С. 32 -36.

7. Altreuther, P. Data of chemistry and Toxilogy of Baytril / P. Altreuther // Veterinari Medical Review. - 1987.- Vol. 2. - P.87-89.

8. Campylobacter Infections: Background, Pathophysiology, Epidemiology. - 2019.

9. Cu, D.T.W. Structure activity relationships of the fluoroquinolones / D.T.W. Cu, P.B. Fernandes // Antimicrobial Agents and Chemotherapy.- 1989.-Vol. 13.- P. 131-135.

10. Gedek, W. Antibakterielle Wirkung von neueren Chinolonen und Nalidixinsaure gegenuber Mastitiserregern vom Rind / W. Gedek // Deutsche tierärztliche Wochenschrift. - 1987.- Т. 94, № 10. - S. 545-548.

11. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Third Informational Supplement. M100-S23. - Clinical and Laboratory Standards Institute (CLSI), 2013